George W Sledge MD(@GeorgeSledge51) 's Twitter Profileg
George W Sledge MD

@GeorgeSledge51

Professor of Medicine, Stanford University; breast cancer doc

ID:1681996543

calendar_today19-08-2013 00:39:01

756 Tweets

3,8K Followers

167 Following

Follow People
The Atlantic(@TheAtlantic) 's Twitter Profile Photo

For citizens of a wealthy country, Americans of every age, at every income level, are unusually likely to die, from guns, drugs, cars, and disease, Derek Thompson writes. How do we fix it?
on.theatln.tc/ObgklNf

account_circle
Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo

The ASCO Plenaries series are back: book your calendar for August 16th, 3pm EST ….because Science can’t wait!

asco.org/meetings-educa…

OncoAlert

The @ASCO Plenaries series are back: book your calendar for August 16th, 3pm EST ….because Science can’t wait! asco.org/meetings-educa… @OncoAlert
account_circle
Oncology Times(@OncologyTimes) 's Twitter Profile Photo

In this issue’s Musings of a Cancer Doctor, George W Sledge MD covers the most exciting presentation at : the results of the DESTINY-Breast04 trial of trastuzumab deruxtecan in HER2-low metastatic breast cancer : ow.ly/f88V50K31AY

In this issue’s Musings of a Cancer Doctor, @GeorgeSledge51 covers the most exciting presentation at #ASCO2022: the results of the DESTINY-Breast04 trial of trastuzumab deruxtecan in HER2-low metastatic breast cancer #bcher: ow.ly/f88V50K31AY
account_circle
Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo

The September Session Abstract Submission Deadline is August 2 at 11:59 PM (EST)

The ASCO Plenary Series....You may ask why? 'Well, because Science simply can't wait!'

Submit at: bit.ly/3NMiz6P

The September #ASCOPlenraySeries Session Abstract Submission Deadline is August 2 at 11:59 PM (EST) The @ASCO Plenary Series....You may ask why? 'Well, because Science simply can't wait!' Submit at: bit.ly/3NMiz6P
account_circle
Susan G. Komen(@SusanGKomen) 's Twitter Profile Photo

Thanks to your donations, Komen is awarding $21.7 million to fund 48 new research projects at 26 institutions across the U.S. These projects are focused primarily on improving patient outcomes for people w/ aggressive & deadly breast cancers. bit.ly/3NcpV37

account_circle
Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo

WE ARE BACK....Yes, The ASCO Plenary Series (2022-2023) is back: The August series opens June 14th!

You may ask Why? Well, because Tomorrow's Science can't wait!

with Melissa L. Johnson Kimmie Ng, MD, MPH George W Sledge MD and an awesome ASCO staff

OncoAlert

bit.ly/3OfdcO5

WE ARE BACK....Yes, The @ASCO Plenary Series (2022-2023) is back: The August series opens June 14th! You may ask Why? Well, because Tomorrow's Science can't wait! with @MLJohnsonMD2 @KimmieNgMD @GeorgeSledge51 and an awesome @ASCO staff @OncoAlert bit.ly/3OfdcO5
account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

Destiny-04. ILD as expected. My thoughts: best in show for breast cancer this year. HER2-low now on the table for ADCs as a class. There is an accompanying NEJM paper. The audience goes wild in a way I have not seen since the HER2 2005 rock concert. Congrats to Dr Modi.

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

Destiny-04, Modi, cont. PFS stat sig with 10.1 vs 5.4 mo with HR 0.51 for HR positive and similar for all pts. OS HR 0.64, 17.5 to 23.9 mo. For HR pos with similar all patients results. Forrest plot shows no differences. Safety profile similar to prior T-DXd trials.

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

Modi plenary talk on trastuzumab deruxtecan for HER2-low MBCl. Phase. 3 trial randomized HER2-low pts to T-DXd or treatment of physicians choice. TPC options include cape, eribilin, gem, paclitaxel or nab-pac with PFS as primary endpoint and OS secondary.

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

Caswell-Jen mortality reduction data tell us how far we have come over the past decades, but also far we have yet to go. Congratulations to my Stanford colleague on a lovely and interesting presentation.

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

My Stanford colleague Caswell-JIn analyzes the effect of metastatic BC therapies using the Cisnet models previously applied to mammography and adj. therapy. The Cisnet models suggest a major impact for HER2-directed therapy, with lesser benefits for ER pos and less still for TNBC

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

Chmura NRG-BR002 systemic Rx +/- SBRT or surgical resection for newly oligometastatic BC. Phase 2R n = 128, then on to Phase 3 planned if initial PFS results positive. Did not make it to Phase 3, with no PFS signal. New mets are the issue. Disappointing results.

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

GREAT discussion by Claudine Isaacs of Georgetown on MBC trials. Should be required exemplar for breast cancer discussants. Thoughtful, with well considered opinions rather than just regurgitation of data.

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

Juric SOLAR-1 alpelisib trial biomarker analysis. Alpelisib previously approved based on PFS improvement with PIK3CA mutant tumors. ITT and biomarker cohorts have similar PFS results. TMB does not alter outcomes. Altered FGFR1/2 do not affect alpelisib benefit. Altered Myc bad.

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

FAKTION trial, cont. pathway-altered pts have best PFS results, and same for OS, where there is no benefit in WT pts. Pathway altered includes PIK3CA/AKT/PTEN. My thoughts: phase 2 data, but impressive in pathway altered.

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

Jones FAKTION randomized phase 2 of fulvestrant +\- AKT inhibitor capivasertib. Addition of capivasertib increases PFS of 10.3 vs 4.8 mo. OS 29.3 vs 23.1 mo. Biomarker NGS results showed pathway alterations in 25% of pts.

account_circle
George W Sledge MD(@GeorgeSledge51) 's Twitter Profile Photo

Kalinsky MAINTAIN trial ORR and CBR not stat significant. Not mature for OS. My thoughts: a modest improvement in PFS, most impressive in pts with ESR1 WT pts (HR 0.30). Like most phase2 trials, not statistically compelling and certainly not blockbuster results.

account_circle